Control
Apr 28 2022 |
et al., Revista da Sociedade Brasileira de Medicina Tropical, doi:10.1590/0037-8682-0565-2022 (date from preprint) | Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors) |
| 50% higher mortality (p=1) and no change in improvement (p=1). Open label RCT late stage hospitalized patients in Brazil showing no significant difference with IL-2 or ixekizumab treatment. Mortality was lower and recovery was greater with colchicine, without statistical significance. | ||